The reiteration of a Buy rating and maintenance of a $15 price target by HC Wainwright & Co. analyst Patrick Trucchio is a positive signal for Oncolytics Biotech. This reaffirms the analyst's confidence in the company's potential, which could lead to increased investor interest and a short-term positive impact on the stock price.